

REMARKS

The specification has been amended to update the cross-reference to related applications as set forth above. The specification has also been amended to insert SEQ ID NO: 16 and 17 on page 8 of the specification as shown above. These sequences have been added into the sequence listing, which has also been updated to the new format. A paper and electronic copy of the updated sequence listing is included with this filing.

The specification has further been amended to delete the sequence of the FLAG peptide on page 31 of the specification. The specification had previously been amended to delete the FLAG sequence from page 11 of the specification.

The amendments to the specification do not introduce new matter and entry of these amendments is respectfully requested.

The claims have been listed to reflect Amendment A provided by Applicants on August 13, 1998, as well as an Examiner's amendment provided in paper 6, mailing date October 26, 1998, and the amendment filed by Applicants October 12, 2000, and entered by Examiner's amendment along with the Notice of Allowance dated May 5, 2006. Claims 30, 35, 36, 37, 41, and 43 present current amendments to the claims. Claim 30 is submitted to correct typographical errors. Process claims 35-37 are amended to recite a process for preparing a 4-1BB polypeptide or soluble 4-1BB polypeptide in order not to read on any non-4-1BB polypeptide expressed by a host cell containing the recited vectors. Thus these amendments are made to more clearly recite the subject matter considered to be the invention. Claim 41 is amended to correct a typographical error. Claim 43 is amended to depend from claim 42 rather than claim 41. Basis for the amendments are found in the specification, and therefore these amendments present no new matter. Entry of the amendments to the claims is respectfully requested.

The allowed claims 29-44 and 47-49 have been renumbered by the Examiner. Applicant requests instead the following renumbering in order to keep the DNA and protein claims grouped together: claims 29 shall be numbered claim 1, claims 30-40 shall be numbered 3-13, claims 41-44 shall be numbered 16-19, claim 47 shall be numbered 2, and claims 48-49 shall be numbered 14 and 15.

The Examiner is invited to call Applicants' attorney at the number below if any questions remain. In addition, if any fees are deemed to be due based on this amendment the Examiner is authorized to charge the required fee to deposit account number 09-0089.

Respectfully submitted,



Christine M. Bellas
Attorney for Applicants
Registration No. 34,122

Immunex Corporation
1201 Amgen Court West
Seattle, Washington 98119-3105
Phone: 206-265-7000

hh041003 8/7/06